Investigación

Farmacología molecular y terapias experimentales

Buscador de publicaciones

Publicaciones

  • Vaskó B, Juhász V, Tóth B, Kurunczi A, Fekete Z, Zolnerciks JK, Kis E, Magnan R, Bidon-Chanal Badia A, Pastor-Anglada M, Hazai E, Bikadi Z, Fülöp F and Krajcsi P.

    Inhibitor selectivity of CNTs and ENTs.

    Xenobiotica . 49(7): 840-851. Nº de citas: 3

    [doi:10.1080/00498254.2018.1501832]

  • Perez-Torras S, Mata-Ventosa A, Drögemöller B, Tarailo-Graovac M, Meijer J, Meinsma R, van Cruchten AG, Kulik W, Viel-Oliva A, Bidon-Chanal A, Ross CJ, Wassermann WW, van Karnebeek CDM, Pastor-Anglada M and van Kuilenburg ABP.

    Deficiency of perforin and hCNT1, a novel inborn error of pyrimidine metabolism, associated with a rapidly developing lethal phenotype due to multi-organ failure

    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE . 1865(6): 1182-1191. Nº de citas: 7

    [doi:10.1016/j.bbadis.2019.01.013]

  • Grañe-Boladeras N, Williams D, Tarmakova Z, Stevanovic K, Villani LA, Mehrabi P, Siu KWM, Pastor-Anglada M and Coe IR.

    Oligomerization of equilibrative nucleoside transporters: a novel regulatory and functional mechanism involving PKC and PP1.

    FASEB JOURNAL . 33(3): 3841-3850. Nº de citas: 8

    [doi:10.1096/fj.201800440RR]

  • Pastor-Anglada M, Urtasun N and Perez-Torras S.

    Intestinal Nucleoside Transporters: Function, Expression, and Regulation.

    COMPREHENSIVE PHYSIOLOGY . 8(3): 1003-1017. Nº de citas: 32

    [doi:10.1002/cphy.c170039]

  • Pastor-Anglada M and Perez-Torras S.

    Who Is Who in Adenosine Transport.

    FRONTIERS IN PHARMACOLOGY . 9: 627-627. Nº de citas: 68

    [doi:10.3389/fphar.2018.00627]

  • Pastor-Anglada M and Perez-Torras S.

    Emerging Roles of Nucleoside Transporters.

    FRONTIERS IN PHARMACOLOGY . 9: 606-606. Nº de citas: 95

    [doi:10.3389/fphar.2018.00606]

  • Urtasun N, Boces-Pascual C, Boix L, Bruix J, Pastor-Anglada M and Perez-Torras S.

    Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma.

    Oncotarget . 8(52): 90185-90196. Nº de citas: 7

    [doi:10.18632/oncotarget.21624]

  • Arimany-Nardi C, Claudio-Montero A, Viel-Oliva A, Schmidtke P, Estarellas C, Barril X, Bidon-Chanal A and Pastor-Anglada M.

    Identification and Characterization of a Secondary Sodium-Binding Site and the Main Selectivity Determinants in the Human Concentrative Nucleoside Transporter 3.

    MOLECULAR PHARMACEUTICS . 14(6): 1980-1987. Nº de citas: 10

    [doi:10.1021/acs.molpharmaceut.7b00085]

  • Minuesa G, Albert C, Pastor-Anglada M, Martinez-Picado J and Koepsell H.

    Response to Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1.

    J PHARMACOL EXP THER . 360(2): 343-345. Nº de citas: 5

    [doi:10.1124/jpet.116.239004]

  • Grañé-Boladeras N, Spring CM, Hanna WJ, Pastor-Anglada M and Coe IR.

    Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir.

    CELLULAR AND MOLECULAR LIFE SCIENCES . 73(23): 4559-4575. Nº de citas: 13

    [doi:10.1007/s00018-016-2288-9]